[Quality control of defrosted cord blood units: results from an inter-laboratory study].
OBJECTIVE
Today, haematopoietic stem cell graft from placental blood concerns more than 15 % of allogeneic grafts. An inter-laboratory study of the quality control of defrosted cord blood units has been coordinated by the French society for cell and tissue bioengineering (SFBCT), with the cord blood bank of Bourgogne Franche-Comté and controlled by the French health products safety agency (Afssaps). The aim of this study is to ensure the inter-laboratory reproducibility of the quality controls practised by the banks during defrosting. The cellular outputs were analyzed according to the defrosting techniques, according to the method used in flow cytometry: single-platform (SP) versus double-platform (DP), or the product nature, i.e. in total blood or miniaturized.


METHODS
Forty-two units of placental blood (USP), which were out of range were provided for defrosting to 14 participating sites. USP were defrosted and controlled according to the procedures of each bank. Once the USP is defrosted, a part of the product was controlled by the site and the other part by Afssaps. Following controls were carried out: numeration of the total nucleated cells (TNC) and of CD34+ cells (made by a SP method in Afssaps) and functional assay.


RESULTS
Concerning TNC, the defrosting sites obtained a cellular output of 94 %+/-28 in day 0 compared with an output of 72 %+/-24 in Afssaps showing a rather good stability of the USP transmitted with an average deviation of 23 %+/-22. The freezing process with or without reduction of volume does not affect this variation. Concerning the numeration of CD34+ cells, the average deviation between the participating sites and Afssaps was 29 %+/-23 compared with 21 %+/-16 for the sites using a SP method against 47 %+/-25 for those using a DP method. The CD34+ outputs are equal to 82 % +/- 60 in day 0 for the participating sites against 52 %+/-20 for Afssaps. For the sites using a DP method, it is stressed that this output is particularly high with a rate of 126 %+/-90 (n=15) whereas it is 62 %+/-20 (n=32) for the sites using a SP method.


CONCLUSIONS
These results underline a good stability of viable CD34+ cells and a greater reliability of the SP methods for the CD34+ cell numeration for these defrosted USP. Lastly, the results of the functional assay regarding the average clonogenicities (equal to 15 %) reinforce the conclusions on the quality of the defrosted products.
Panterne
B
B
Afssaps, DLC, unité produits sanguins et thérapie cellulaire, 143/147, boulevard Anatole-France, 93285 St-Denis cedex, France. Beatrice.panterne@afssaps.sante.fr
Richard
M-J
MJ
Sabatini
C
C
Pouthier
F
F
Mouillot
L
L
Bardey
D
D
Boulanger
F
F
Créa
S
S
Dal Cortivo
L
L
Decot
V
V
Fleury-Cappellesso
S
S
Giraud
C
C
Lapierre
V
V
Léauté
A-G
AG
Le Berre
C
C
Lemarié
C
C
Piard
N
N
Rapatel
C
C
Rosenzwajg
M
M
D018952:Antigens, CD34 / Q000032:analysis; D001772:Blood Cell Count; D001793:Blood Preservation / Q000379:methods / Q000592:standards*; D002467:Cell Nucleus / Q000648:ultrastructure; D002999:Clone Cells / Q000166:cytology; D003114:Colony-Forming Units Assay; D036101:Cord Blood Stem Cell Transplantation / Q000592:standards*; D015925:Cryopreservation / Q000592:standards*; D005260:Female; D005312:Fetal Blood; D005602:France; D006412:Hematopoietic Stem Cells / Q000648:ultrastructure; D006801:Humans; D007231:Infant, Newborn; D007753:Laboratories; D010920:Placenta; D011247:Pregnancy; D011786:Quality Control; D012955:Societies, Medical / Q000592:standards
D018952:Antigens, CD34